Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub-Agha, Ibrahim ; Chabannon, Christian ; Bader, Peter ; Basak, Grzegorz W. ; Bonig, Halvard ; Ciceri, Fabio ; Corbacioglu, Selim ; Duarte, Rafael F. ; Einsele, Hermann ; Hudecek, Michael ; Kersten, Marie José ; Köhl, Ulrike ; Kuball, Jürgen ; Mielke, Stephan ; Mohty, Mohamad ; Murray, John ; Nagler, Arnon ; Robinson, Stephen ; Saccardi, Riccardo ; Sanchez-Guijo, Fermin ; Snowden, John A. ; Srour, Micha ; Styczynski, Jan ; Urbano-Ispizua, Alvaro ; Hayden, Patrick J. ; Kröger, Nicolaus

---

Alternative Links zum Volltext:DOIVerlag

---

Details

Dokumentenart:	Artikel
Titel eines Journals oder einer Zeitschrift:	Haematologica
Verlag:	Ferrata-Storti Foundation
Ort der Veröffentlichung:	PAVIA
Band:	105
Nummer des Zeitschriftenheftes oder des Kapitels:	2
Seitenbereich:	S. 297-316
Datum:	2019
Institutionen:	Medizin > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
Identifikationsnummer:	Wert Typ 10.3324/haematol.2019.229781 DOI
Stichwörter / Keywords:	CYTOKINE-RELEASE SYNDROME; HAPLOIDENTICAL DONOR TRANSPLANTATION; HEMATOLOGICAL MALIGNANCIES; PEDIATRIC-PATIENTS; PLASMA-LEVELS; CAR THERAPY; BONE-MARROW; REMISSIONS; TISAGENLECLEUCEL; EXPRESSION;
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	50394

Indiziert in

Web of Science

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLopenCostxMetaDissPlus

---

Zusammenfassung

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagen-lecleucel (Kymriah (TM)) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell ...

Zusammenfassung

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagen-lecleucel (Kymriah (TM)) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta (TM)) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications induding cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.

---

---

Metadaten zuletzt geändert: 11 Okt 2021 13:04

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)